Paolo Calabresi to Parkinson Disease
This is a "connection" page, showing publications Paolo Calabresi has written about Parkinson Disease.
Connection Strength
2.049
-
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease. Cell Death Dis. 2018 02 12; 9(2):204.
Score: 0.292
-
Levodopa in Parkinson's Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018; 16(8):1239-1252.
Score: 0.290
-
Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. Mov Disord. 2018 07; 33(6):867-876.
Score: 0.289
-
Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit. Biol Psychiatry. 2016 Mar 01; 79(5):402-414.
Score: 0.246
-
New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet Neurol. 2013 Aug; 12(8):811-21.
Score: 0.214
-
Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Brain. 2009 Feb; 132(Pt 2):285-7.
Score: 0.156
-
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain. 2004 Jul; 127(Pt 7):1661-9.
Score: 0.113
-
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol. 2018 12; 84(6):797-811.
Score: 0.077
-
Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. BMJ Open. 2017 Nov 22; 7(11):e018177.
Score: 0.072
-
Diagnostic utility of cerebrospinal fluid a-synuclein in Parkinson's disease: A systematic review and meta-analysis. Mov Disord. 2017 Oct; 32(10):1389-1400.
Score: 0.071
-
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep; 32(9):1264-1310.
Score: 0.071
-
Cerebrospinal fluid ß-glucocerebrosidase activity is reduced in parkinson's disease patients. Mov Disord. 2017 Oct; 32(10):1423-1431.
Score: 0.071
-
Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques. PLoS One. 2017; 12(7):e0181677.
Score: 0.070
-
Differential role of CSF fatty acid binding protein 3, a-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Alzheimers Res Ther. 2017 Jul 28; 9(1):52.
Score: 0.018